15
total announcements
KILITCH.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹766 Cr
P/E (TTM)
24.9
P/E (Forward)
14.3
EPS (TTM)
₹8.80
52W Low
₹117.25
52W High
₹267.90
Dividend Yield
0.00%
Beta
0.31
Price / Book
2.7
Debt / Equity
32.0
Revenue (TTM)
₹237 Cr
Gross Margin
47.33%
Operating Margin
4.11%
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding Resignation of Mr. Venkita Subramanian Rajan as Non-Executive Independent Director of the company with immediate effect.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the acceptance/rejection of securities received for dematerialisation during the quarter ended 30 September, 2026.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on August 27, 2026. The report details the voting results for the resolutions passed at the meeting, including the approval of the audited financial statements and the appointment of Mr. Mukund P. Mehta as a director.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 27, 2026. The meeting was held through video conferencing and the following items of business were transacted: receiving and approving the Audited Standalone and Consolidated Financial Statements, re-appointing Mr. Mukund Mehta as a director, approving performance linked pay to executive directors, and ratifying the remuneration to the Cost Auditor.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has submitted a monitoring agency report for the quarter ended June 30, 2026, related to the right issue of equity shares for an amount aggregating to Rs. 49.92 crore. The report indicates no deviation from the objects of the issue and provides an objective view of the utilization of the issue proceeds.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has published unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026, showing a net profit of Rs. 12.315 lakhs for the period.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 505.24 lakhs and earnings per share of Rs. 1.45.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange about the publication of a newspaper notice regarding the 34th Annual General Meeting (AGM) and the sale of a secured asset by Aadhar Housing Finance Limited (AHFL).
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding 'AGM Notice and Annual Report - Physical Intimation to Shareholders'. The company has issued letters to shareholders providing the weblink of the website from where the Annual Report for FY 2025-26 and Notice of AGM can be accessed.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding 'Intimation of Book Closure for the purpose of AGM'. The company will close the Register of Members and Share Transfer Register from August 20, 2026, to August 27, 2026, and will hold its 34th Annual General Meeting on August 27, 2026, through Video Conferencing and other Audio Visual Means.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026, to consider and pass various resolutions, including the adoption of financial statements, appointment of a director, and ratification of remuneration to the Cost Auditor.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding Outcome of Board Meeting held on July 28, 2026, where the Board of Directors considered and approved various items, including the Notice of 34 Annual General Meeting, appointment of a Scrutinizer, and re-appointment of Cost Auditors.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.